2021;384(5):403-416. doi:10.1056/NEJMoa2035389 22. Izda V, Jeffries MA, Sawalha AH. COVID-19: A review of therapeutic strategies and vaccine candidates. Clin Immunol. 2021;222:108634. doi:10.1016/j.clim.2020.108634 23. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS- CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99- 111. doi:10.1016/S0140-6736(20)32661-1 24. Knoll MD, Wonodi C. Oxford–AstraZeneca COVID-19 vaccine efficacy. The Lancet. 2021;397(10269):72-74. doi:10.1016/ S0140-6736(20)32623-4 25. Sadoff J, Le Gars M, Shukarev G, et al. Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine. N Engl J Med. Published online January 13, 2021. doi:10.1056/ NEJMoa2034201 26. Janssen Vaccines & Prevention B.V. A Randomized, Double- Blind, Placebo-Controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV- 2-Mediated COVID-19 in Adults Aged 18 Years and Older. clinicaltrials.gov; 2021. Accessed February 15, 2021. https:// clinicaltrials.gov/ct2/show/NCT04505722 27. Janssen Investigational COVID-19 Vaccine: Interim Analysis of Phase 3 Clinical Data Released. National Institutes of Health (NIH). Published January 29, 2021. Accessed February 16, 2021. https://www.nih.gov/news-events/news-releases/janssen- investigational-covid-19-vaccine-interim-analysis-phase-3- clinical-data-released 28. Keech C, Albert G, Cho I, et al. Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N Engl J Med. 2020;383(24):2320-2332. doi:10.1056/NEJMoa2026920 29. Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial | Novavax Inc. - IR Site. Accessed February 16, 2021. https://ir.novavax.com/news-releases/news-release- details/novavax-covid-19-vaccine-demonstrates-893- efficacy-uk-phase-3 30. Mercado NB, Zahn R, Wegmann F, et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature. 2020;586(7830):583-588. doi:10.1038/s41586-020- 2607-z 31. Guebre-Xabier M, Patel N, Tian J-H, et al. NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge. Vaccine. 2020;38(50):7892-7896. doi:10.1016/j.vaccine.2020.10.064 32. Levine-Tiefenbrun M, Yelin I, Katz R, et al. Decreased SARS- CoV-2 Viral Load Following Vaccination. Infectious Diseases (except HIV/AIDS); 2021. doi:10.1101/2021.02.06.21251283 33. Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020;382(19):1787-1799. doi:10.1056/NEJMoa2001282 34. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial - PubMed. Accessed February 14, 2021. https:// pubmed.ncbi.nlm.nih.gov/33031764/ 35. WHO Solidarity Trial Consortium, Pan H, Peto R, et al. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med. 2021;384(6):497-511. doi:10.1056/NEJMoa2023184 36. Cavalcanti AB, Zampieri FG, Rosa RG, et al.
7. Cheng VC-C, Wong S-C, Chuang VW-M, et al. The role of community-wide wearing of face mask for control of coronavirus disease 2019 (COVID-19) epidemic due to SARS-CoV-2. J Infect. 2020;81(1):107-114. doi:10.1016/j. jinf.2020.04.024 8. Clapp PW, Sickbert-Bennett EE, Samet JM, et al. Evaluation of Cloth Masks and Modified Procedure Masks as Personal Protective Equipment for the Public During the COVID-19 Pandemic. JAMA Intern Med. Published online December 10, 2020. doi:10.1001/jamainternmed.2020.8168 9. Chu DK, Akl EA, Duda S, Solo K, Yaacoub S, Schünemann HJ. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. Lancet. 2020;395(10242):1973-1987. doi:10.1016/S0140-6736(20)31142- 9 10. Tang JW, Tambyah PA, Hui DS. Emergence of a new SARS- CoV-2 variant in the UK. J Infect. Published online December 28, 2020. doi:10.1016/j.jinf.2020.12.024 11. Tang JW, Toovey OTR, Harvey KN, Hui DDS. Introduction of the South African SARS-CoV-2 variant 501Y.V2 into the UK. J Infect. Published online January 17, 2021. doi:10.1016/j. jinf.2021.01.007 12. CDC. COVID-19 and Your Health. Centers for Disease Control and Prevention. Published February 11, 2020. Accessed February 14, 2021. https://www.cdc.gov/coronavirus/2019- ncov/your-health/effective-masks.html 13. Brooks JT. Maximizing Fit for Cloth and Medical Procedure Masks to Improve Performance and Reduce SARS-CoV-2 Transmission and Exposure, 2021. MMWR Morb Mortal Wkly Rep. 2021;70. doi:10.15585/mmwr.mm7007e1 14. Joo H. Decline in COVID-19 Hospitalization Growth Rates Associated with Statewide Mask Mandates — 10 States, March–October 2020. MMWR Morb Mortal Wkly Rep. 2021;70. doi:10.15585/mmwr.mm7006e2 15. Matrajt L, Leung T. Evaluating the Effectiveness of Social Distancing Interventions to Delay or Flatten the Epidemic Curve of Coronavirus Disease. Emerg Infect Dis. 2020;26(8):1740-1748. doi:10.3201/eid2608.201093 16. Jones NR, Qureshi ZU, Temple RJ, Larwood JPJ, Greenhalgh T, Bourouiba L. Two metres or one: what is the evidence for physical distancing in covid-19? BMJ. 2020;370:m3223. doi:10.1136/bmj.m3223 17. CDC. Community, Work, and School. Centers for Disease Control and Prevention. Published February 11, 2020. Accessed February 16, 2021. https://www.cdc.gov/ coronavirus/2019-ncov/community/ventilation.html 18. van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS- CoV-1. New England Journal of Medicine. 2020;382(16):1564- 1567. doi:10.1056/NEJMc2004973 19. CDC. COVID-19 and Your Health. Centers for Disease Control and Prevention. Published October 28, 2020. Accessed February 11, 2021. https://www.cdc.gov/coronavirus/2019- ncov/prevent-getting-sick/how-covid-spreads.html 20. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577 21. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med.
22
Made with FlippingBook Digital Publishing Software